Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health …
Medical - Diagnostics & Research
US, Salt Lake City [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Myriad Genetics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | 1.1200 | 1.457 | 723 | 720 | 80 | 89 | 159 | 172 | 134 | 148 | 366 | 341 |
| 2016 | 1.7900 | 1.646 | 753 | 755 | 125 | 71 | 193 | 131 | 166 | 95 | 359 | 410 |
| 2017 | 0.3200 | 1.019 | 771 | 764 | 21 | 98 | 96 | 135 | 49 | 94 | 476 | 373 |
| 2018 | 1.8900 | 1.206 | 772 | 773 | 131 | 17 | 113 | 86 | 57 | 29 | 467 | 420 |
| 2019 | 0.0600 | 1.715 | 851 | 857 | 4 | -40 | 86 | 47 | 8 | -44 | 555 | 673 |
| 2020 | 0.0626 | -0.190 | 851 | 639 | 4 | -1,175 | 86 | -1,114 | 8 | -1,396 | 555 | 489 |
| 2021 | - | -0.725 | - | 691 | - | -47 | - | 14 | - | -229 | - | 529 |
| 2022 | -0.3500 | -0.343 | 690 | 670 | -27 | -35 | 14 | 16 | -188 | -171 | 599 | 668 |
| 2023 | -1.3900 | -0.304 | 678 | 751 | -112 | -263 | -67 | 18 | -123 | -188 | 514 | 592 |
| 2024 | -3.1800 | 0.128 | 753 | 840 | -263 | 9 | -186 | -75 | -257 | -154 | 572 | 662 |
| 2025 | - | 0.149 | - | 881 | - | 13 | - | -78 | - | -161 | - | 694 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |